IGC Announces Phytocannabinoid Focused Pharmaceutical Unit

Bethesda, MD, June 10, 2015 (GLOBE NEWSWIRE) -- IGC, Inc. (NYSE-MKT: IGC) announces the third vertical in its

effort to gain a leading position in the emerging legal cannabis

industry. Our strategy is to develop a product portfolio of

phytocannabinoid-based therapies for the treatment of a wide range

of therapeutic indications including pain, epilepsy, and other

niche severe terminal diagnosis, which are life altering or life

Most recently, the company applied for a provisional patent

based on a novel therapy that uses cannabinoid extracts for the

treatment of seizures in dogs and cats. The therapy, which is

expected to also have applications in humans, is administered using

a variety of delivery technologies. We expect to establish

metabolic profiling and apply to the FDA for trials.

To facilitate the development of the product portfolio, IGC is

entering into partnerships with a range of organizations that can

provide cost effective solutions for metabolic profiling, clinical

trials, and regulatory approvals that in most cases will be

necessary to eventually commercialize our products.

"The Company is also continuing to assemble an international

network of doctors, veterinarians, and researchers with extensive

expertise in various indications, medicines containing controlled

substances, plant-based products, extraction technologies, and drug

delivery technologies. In addition, we have assembled experts

in patent law, clinical trials, and regulatory procedures," said

Ram Mukunda, IGC's CEO.

Mukunda added, "Among our senior advisors is Dr. Ranga Krishna

who founded International Pharma Trials ("IPT"), a company with

over 150 employees that assists a number of U.S. pharmaceutical

companies in performing clinical trials. IPT has a specialty

in pain and epilepsy. Dr. Krishna himself is a neurologist

with a sub-specialty in epilepsy surgery."

"Jack Lynch who has over 50 years of experience in practice

before US District and Appellate courts and the US Patent and

Trademark Office is another of our key senior advisors leading our

intellectual property filing strategy and was instrumental in this

filing as well as other filings, which we will be disclosing,"

To help our shareholders and potential investors better

understand our direction, we have deployed a new website at

www.igcinc.usthat explains both

our current electronics business and our expansion into the

phytocannabinoid business as well as our strategy and the synergies

between these businesses. The website also provides

background on phytocannabinoids and why they hold hope for various

ailments. We have also restarted our presence on social media:

twitter (@IGCIR)," said Mukunda.

Our launch of the pharmaceutical unit is part of IGC's

previously articulated efforts to drive shareholder value by

building three segments within the legal cannabis sector: a)

facilities and technologies, b) legal cannabis research and

investment banking, and c) pharmaceuticals based on

Based in Bethesda, Maryland, IGC, Inc. is taking

defensible, high growth, high margin positions in two of the

world's fastest growing industries electronics and cannabis.

Our involvement in the electronics and cannabis industries

creates unique synergies and advantages that we believe will be

highly profitable in the short and long term. Our

website: www.igcinc.us. Follow

us on twitter (@IGCIR).

Forward-looking Statements:

Some of the statements contained in this press

release that are not historical facts constitute forward- looking

statements under the federal securities laws. Forward-looking

statements can be identified by the use of the words "may," "will,"

"should," "could," "expects," "plans," "anticipates," "believes,"

"estimates," "predicts," "intends," "potential," "proposed" or the

negative of those terms. The term "crowd funding" or "crowdfunding"

is not a recognized regulatory term and is meant as a reference to

offerings of investment securities under the JOBS Act of 2012 for

regulations both currently adopted and to be adopted in the future

by the Securities & Exchange Commission and FINRA as a result

of that legislation. These statements are not a guarantee of future

developments and are subject to risks, uncertainties and other

factors, some of which are beyond IGC's control and are difficult

to predict. Consequently, actual results may differ materially from

information contained in the forward-looking statements as a result

of future changes or developments in our business, our acquisition

and diversification strategy, our competitive environment,

infrastructure demands, iron ore availability and governmental,

regulatory, political, economic, legal and social conditions in,

among other places, China and India. Except as required by federal

securities laws, IGC undertakes no obligation to publicly update

any forward- looking statements, whether as a result of new

information, future events, or otherwise. Other factors and risks

that could cause or contribute to actual results differing

materially from such forward- looking statements have been

discussed in greater detail in IGC's Form 10- K for fiscal year

ended March 31, 2014, and in subsequent reports filed with the U.S.

IGC Phytocannabinoids

IGC Pharmaceutical products

Legal Cannabis investment banking